Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 8/20 | 0.62 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047118 | 0.94 | LIMK2 (0.66) | LIMK2CACNA1HCACNA1BPTGDR2TDP1 | |
| SCHEMBL3049525 | 0.83 | CACNA1H (0.56) | LIMK2CACNA1HCACNA1BPTGDR2TDP1 | |
| SCHEMBL2897956 | 0.81 | CCR1 (0.60) | CACNA1HCACNA1BPTGDR2TDP1L3MBTL1 | |
| SCHEMBL4043636 | 0.79 | PTGDR2 (0.57) | LIMK2CACNA1HCACNA1BPTGDR2TDP1 | |
| SCHEMBL3274401 | 0.79 | POLB (0.72) | CACNA1HCACNA1BPTGDR2TDP1L3MBTL1 | |
| SCHEMBL3047854 | 0.79 | PTGDR2 (0.57) | LIMK2CACNA1HCACNA1BPTGDR2TDP1 | |
| Trifluoroacetic Acid SCHEMBL3059322 | 0.78 | LIMK2 (0.46) | LIMK2CACNA1HCACNA1BPTGDR2TDP1 | |
| SCHEMBL3047254 | 0.77 | CACNA1H (0.59) | LIMK2CACNA1HCACNA1BPTGDR2TDP1 | |
| SCHEMBL3054429 | 0.76 | LIMK2 (0.61) | LIMK2CACNA1HCACNA1B | |
| SCHEMBL8752434 | 0.76 | FFAR1 (0.65) | CACNA1HCACNA1BPTGDR2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2012-11-22 | — | — | US | disclosed |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-29 | — | — | US | disclosed |
| EP-2057116-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008050167-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | LIMK2 3067/4885CACNA1H 1604/4885CACNA1B 1550/4885 |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | LIMK2 2826/4885CACNA1H 1596/4885CACNA1B 1486/4885 |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | LIMK2 3322/4885CACNA1H 1681/4885CACNA1B 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.